Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Victoria detects H5N1 avian influenza strain

It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Content from other channels on our network

The water sector's biggest problem may not be underground

Climate reporting is exposing a problem bigger than emissions

How Energy Technology can advance net zero journeys

When sustainability targets outpace building systems

The energy advantage: The next growth opportunity for Australia and New Zealand

How flow meters improve the performance of your dosing pumps

NSW Government supporting local exporters

CEF report calls for a national iron and steel decarbonisation strategy

Duratec awarded a construction management contract for Orica hydrogen hub

Kardex launches PortScale weighing solution in Australia

The ISSA Cleaning & Hygiene Expo Brings Infection Prevention to the forefront

Finalists named for 2026 Health Minister's Award for Nursing Trailblazers

"Fake podiatrist" to serve two-year jail sentence in the community following appeal

How agentic orchestration can help solve health care's workforce challenge

The Organisations That Will Lead This Sector in Five Years, Are Making Different Decisions Right Now.